Literature DB >> 16267375

Effects of estrogen on platelet reactivity after transient forebrain ischemia in rats.

Marguerite T Littleton-Kearney1, Jessica M Gaines, Kevin P Callahan, Stephanie J Murphy, Patricia D Hurn.   

Abstract

Estrogen's prothrombotic effects are of increasing concern, particularly in stroke risk and recovery. Using an ischemic rodent model, the authors sought to determine (a) if estrogen replacement increases postischemic platelet reactivity, (b) if changes in estrogen status alter intraplatelet endothelial nitric oxide synthase (eNOS) synthesis, and (c) if estrogen-mediated effects on platelets alter cerebral blood flow during reperfusion. Intact (I), ovariectomized (OVX), and OVX + 17 beta-estradiol (E50) rats were subjected to 30 min of forebrain ischemia and 60 min of reperfusion. Using the platelet activation marker P-selectin, postischemic platelet reactivity was quantified by flow cytometry. In a separate cohort (I, OVX, E50), the authors quantified platelet eNOS by Western blot. Another cohort (OVX, E50) was subjected to ischemia/reperfusion, and cerebral blood flow was determined using the iodoantipyrine technique. Collagen-stimulated platelet P-selectin expression was increased in the OVX rats at 60 min of reperfusion, and this effect was reversed by estrogen treatment. No differences in platelet eNOS expression were detected among groups. Cerebral blood flow at 60 min reperfusion was comparable between the OVX and the E50 rats. The authors conclude that during reper-fusion, estrogen deficiency increases postischemic platelet sensitivity to stimuli in estrogen-deficient rats. Estrogen treatment mitigates effects of estrogen loss on platelets, but this early effect is apparently not caused by intraplatelet eNOS depression. Neither estrogen deficiency nor estrogen treatment changes early postischemic regional brain blood flow. In this rodent global cerebral ischemic model, physiologic doses of estrogen are not deleterious to platelet reactivity and may initially reduce postischemic platelet reactivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267375      PMCID: PMC2678714          DOI: 10.1177/1099800405276832

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  46 in total

1.  Platelet collagen receptors and risk prediction in stroke and coronary artery disease.

Authors:  T J Kunicki; Z M Ruggeri
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

2.  Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets.

Authors:  Muthuvel Jayachandran; Virginia M Miller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-07       Impact factor: 4.733

3.  Effects of hormone replacement therapy on blood platelets.

Authors:  A Thijs; W M van Baal; M J van der Mooren; P Kenemans; A M Dräger; P C Huijgens; C D A Stehouwer
Journal:  Eur J Clin Invest       Date:  2002-08       Impact factor: 4.686

4.  Course of platelet activation markers after ischemic stroke.

Authors:  Lars Marquardt; Andreas Ruf; Ulrich Mansmann; Ralph Winter; Matthias Schuler; Florian Buggle; Horst Mayer; Armin J Grau
Journal:  Stroke       Date:  2002-11       Impact factor: 7.914

5.  Neuroprotective effects of female gonadal steroids in reproductively senescent female rats.

Authors:  N J Alkayed; S J Murphy; R J Traystman; P D Hurn; V M Miller
Journal:  Stroke       Date:  2000-01       Impact factor: 7.914

6.  Estrogen restores postischemic pial microvascular dilation.

Authors:  Y Watanabe; M T Littleton-Kearney; R J Traystman; P D Hurn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-07       Impact factor: 4.733

7.  Expression of P-selectin and intercellular adhesion molecule-1 in human brain after focal infarction or cardiac arrest.

Authors:  S Love; R Barber
Journal:  Neuropathol Appl Neurobiol       Date:  2001-12       Impact factor: 8.090

8.  Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion.

Authors:  Z G Zhang; L Zhang; W Tsang; A Goussev; C Powers; K L Ho; D Morris; S S Smyth; B S Coller; M Chopp
Journal:  Brain Res       Date:  2001-09-07       Impact factor: 3.252

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Progesterone administration during reperfusion, but not preischemia alone, reduces injury in ovariectomized rats.

Authors:  Stephanie J Murphy; Marguerite T Littleton-Kearney; Patricia D Hurn
Journal:  J Cereb Blood Flow Metab       Date:  2002-10       Impact factor: 6.200

View more
  4 in total

Review 1.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

2.  Effects of estrogen on postischemic pial artery reactivity to ADP.

Authors:  Min Li; Emil Zeynalov; Xiaoling Li; Chikao Miyazaki; Raymond C Koehler; Marguerite T Littleton-Kearney
Journal:  Microcirculation       Date:  2009-04-04       Impact factor: 2.628

Review 3.  Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke.

Authors:  Rodney M Ritzel; Lori A Capozzi; Louise D McCullough
Journal:  Horm Behav       Date:  2012-04-24       Impact factor: 3.587

4.  Activated platelets from diabetic rats cause endothelial dysfunction by decreasing Akt/endothelial NO synthase signaling pathway.

Authors:  Keiko Ishida; Kumiko Taguchi; Takayuki Matsumoto; Tsuneo Kobayashi
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.